UC
MCID: ULC004
MIFTS: 80

Ulcerative Colitis (UC)

Categories: Blood diseases, Gastrointestinal diseases

Aliases & Classifications for Ulcerative Colitis

MalaCards integrated aliases for Ulcerative Colitis:

Name: Ulcerative Colitis 38 12 76 25 37 43 3 15 73
Inflammatory Bowel Disease, Ulcerative Colitis Type 25
Chronic Left-Sided Ulcerative Colitis 73
Left-Sided Ulcerative Colitis 12
Left Sided Ulcerative Colitis 73
Idiopathic Proctocolitis 25
Colitis, Ulcerative 44
Colitis Ulcerative 55
Colitis Gravis 25
Uc 25

Classifications:



External Ids:

Disease Ontology 12 DOID:8577
ICD10 33 K51 K51.9
ICD9CM 35 556 556.5 556.9
MeSH 44 D003093
NCIt 50 C2952
KEGG 37 H01466

Summaries for Ulcerative Colitis

MedlinePlus : 43 Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Ulcerative Colitis, also known as inflammatory bowel disease, ulcerative colitis type, is related to pyoderma gangrenosum and colonic disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Ulcerative Colitis is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Benzocaine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include Bone, colon and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A colitis that is predominantly confined to the mucosa located in colon and includes characteristic ulcers, or open sores.

Genetics Home Reference : 25 Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectum and colon, which make up most of the length of the large intestine. The inflammation usually causes open sores (ulcers) to develop in the large intestine. Ulcerative colitis usually appears between ages 15 and 30, although it can develop at any age. The inflammation tends to flare up multiple times throughout life, which causes recurring signs and symptoms.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

Wikipedia : 76 Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon... more...

Related Diseases for Ulcerative Colitis

Diseases related to Ulcerative Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 785)
# Related Disease Score Top Affiliating Genes
1 pyoderma gangrenosum 32.7 CXCL8 NOD2 TNF
2 colonic disease 32.7 MLH1 MSH2 NOD2
3 pouchitis 32.7 CXCL8 IL10 NOD2 TLR4
4 inflammatory bowel disease 32.0 ABCB1 ATG16L1 CRP CXCL8 IL10 IL1B
5 colitis 31.7 ABCB1 ATG16L1 CXCL8 IL10 IL1B IL2
6 crohn's disease 31.4 ABCB1 ATG16L1 CRP IL10 IL23R IRGM
7 pyoderma 31.3 CXCL8 NOD2 TNF
8 crohn's colitis 31.2 CXCL8 IL1B IL2 NOD2 TNF
9 cytomegalovirus infection 31.1 CXCL8 IL1B TNF
10 ileitis 31.1 MPO NOD2 TLR4 TNF
11 proctitis 31.0 CRP MPO TNF
12 bronchiolitis obliterans 30.7 CXCL8 IL10 TNF
13 arthritis 30.7 CXCL8 IL10 IL1B NOD2 TNF
14 celiac disease 1 30.7 IL10 IL2 MYO9B TNF
15 psoriasis 30.6 CXCL8 IL10 IL1B IL2 IL23R TNF
16 uveitis 30.5 IL10 NOD2 TNF
17 spondylitis 30.5 CRP IL23R NOD2 TNF
18 autoimmune disease 30.5 IL10 IL1B IL2 TNF
19 bronchiolitis 30.5 CRP CXCL8 IL10 TLR4 TNF
20 spondyloarthropathy 1 30.4 CRP NOD2 TLR4 TNF
21 pneumonia 30.4 CRP CXCL8 IL10 IL1B MPO TLR4
22 ileocolitis 30.4 MYO9B NOD2 TNF
23 osteomyelitis 30.4 CXCL8 IL10 IL1B TNF
24 acute pancreatitis 30.3 CRP CXCL8 IL10 MPO
25 inflammatory bowel disease 5 30.3 ATG16L1 IL23R NOD2
26 meningitis 30.2 CRP CXCL8 IL10 IL1B TNF
27 aspergillosis 30.2 IL10 TLR4 TNF
28 familial mediterranean fever 30.2 CRP IL1B NOD2 TNF
29 hematopoietic stem cell transplantation 30.2 IL10 IL2 TNF
30 extrinsic allergic alveolitis 30.2 CXCL8 IL10 IL1B MPO
31 endomyocardial fibrosis 30.1 IL10 TNF
32 autoimmune inner ear disease 30.1 MPO TNF
33 peptic ulcer disease 30.1 CXCL8 IL10 IL1B TNF
34 lung disease 30.1 CXCL8 IL10 IL1B MPO TNF
35 pericarditis 30.1 CRP IL1B TNF
36 alopecia areata 30.1 IL1B IL2 TNF
37 wells syndrome 30.0 CRP CXCL8 IL1B IL2
38 colorectal adenocarcinoma 30.0 MLH1 MSH2 MUC2
39 human immunodeficiency virus infectious disease 30.0 IL10 IL2 TNF
40 appendicitis 30.0 CRP CXCL8 IL10 IL1B MPO TNF
41 duodenal ulcer 30.0 CXCL8 IL1B TNF
42 psoriatic arthritis 30.0 CRP IL1B IL23R NOD2 TNF
43 pleurisy 30.0 CRP CXCL8 IL2 MPO TNF
44 spondylarthropathy 30.0 NOD2 TLR4 TNF
45 obstructive jaundice 29.9 CRP CXCL8 TNF
46 transverse myelitis 29.9 CXCL8 IL10 TNF
47 sarcoidosis 1 29.9 IL1B IL2 NOD2 TNF
48 eales disease 29.9 IL10 IL1B TNF
49 tonsillitis 29.9 CXCL8 IL1B IL2 TNF
50 chronic fatigue syndrome 29.9 IL10 IL1B IL2 TNF

Comorbidity relations with Ulcerative Colitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Obstruction
Iron Deficiency Anemia Paralytic Ileus
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ulcerative Colitis:



Diseases related to Ulcerative Colitis

Symptoms & Phenotypes for Ulcerative Colitis

UMLS symptoms related to Ulcerative Colitis:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CXCL8 IL10 IL1B IL2 MLH1 MPO
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CXCL8 IL10 IL1B IL2 MLH1 MPO
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.83 NOD2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.83 CRP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.83 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.83 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.83 CRP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.83 TLR4
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.83 IL10
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.83 IL10
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.83 IL10
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.83 CRP IL10 NOD2 TLR4
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.83 NOD2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.83 CRP

MGI Mouse Phenotypes related to Ulcerative Colitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 ABCB1 ATG16L1 IL10 IL1B IL2 IL23R
2 cardiovascular system MP:0005385 10.07 ABCB1 ATG16L1 CRP IL10 IL1B IL2
3 digestive/alimentary MP:0005381 10.06 ABCB1 ATG16L1 IL10 IL2 IL23R MLH1
4 homeostasis/metabolism MP:0005376 10 ABCB1 ATG16L1 CRP IL10 IL1B IL2
5 immune system MP:0005387 9.83 ABCB1 ATG16L1 CRP IL10 IL1B IL2
6 neoplasm MP:0002006 9.28 IL10 IL1B IL2 IL23R MLH1 MSH2

Drugs & Therapeutics for Ulcerative Colitis

Drugs for Ulcerative Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
2 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
3
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
4
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
5
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
6
leucovorin Approved Phase 4,Phase 2,Not Applicable 58-05-9 6006 143
7
Tocopherol Approved, Investigational Phase 4,Phase 2,Not Applicable 1406-66-2 14986
8
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
9
Copper Approved, Investigational Phase 4 7440-50-8 27099
10
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
11
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
15
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
16
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
17
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
18 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 943609-66-3
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
20
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
22
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
23
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
24
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 443-48-1 4173
25
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
26
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
27
Nicotine Approved Phase 4 54-11-5 942 89594
28
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
29
Methotrexate Approved Phase 4,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
30
Vancomycin Approved Phase 4,Phase 1,Not Applicable 1404-90-6 14969 441141
31
Certolizumab pegol Approved Phase 4,Phase 2 428863-50-7
32
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 1 477600-75-2
33
Magnesium citrate Approved Phase 4 3344-18-1
34
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
35
Losartan Approved Phase 4 114798-26-4 3961
36
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
37
Caffeine Approved Phase 4 58-08-2 2519
38
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
39
Thioguanine Approved Phase 4 154-42-7 2723601
40
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
41
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 59-02-9 14985
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 59-30-3 6037
44
Vitamin C Approved, Nutraceutical Phase 4,Not Applicable 50-81-7 5785 54670067
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
46 Tocotrienol Investigational Phase 4,Phase 2,Not Applicable 6829-55-6
47
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2920-86-7
48 Mesalamine Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 89-57-6
49 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1024)
# Name Status NCT ID Phase Drugs
1 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
2 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
3 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
4 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
5 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
6 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
7 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
8 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
9 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
10 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
11 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
12 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
13 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
14 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
15 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
16 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
17 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4 Infliximab
18 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4 Golimumab
19 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
20 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
21 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4 Mesalamine
22 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
23 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
24 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
25 Adacolumn in Refractory UC Patients Trial Completed NCT01481142 Phase 4
26 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4 mesalamine
27 Predicting Response to Standardized Pediatric Colitis Therapy Completed NCT01536535 Phase 4 Mesalamine;Corticosteroid;Corticosteroids then mesalamine
28 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
29 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed NCT02318667 Phase 4
30 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
31 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
32 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
33 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
34 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
35 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
36 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
37 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
38 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
39 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
40 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
41 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
42 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
43 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
44 Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Recruiting NCT02345733 Phase 4 Antibiotic cocktail
45 Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis Recruiting NCT02770040 Phase 4 Infliximab
46 Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis Recruiting NCT02921555 Phase 4 Methylprednisolone;Prednisone
47 Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients Recruiting NCT03581149 Phase 4 Sodium Picosulfate/Magnesium Citrate Laxative;2L polyethylene glycol/ascorbic acid
48 Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis Recruiting NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
49 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Recruiting NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
50 An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis Recruiting NCT03237260 Phase 4 Vedolizumab

Search NIH Clinical Center for Ulcerative Colitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ulcerative Colitis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: colitis, ulcerative

Genetic Tests for Ulcerative Colitis

Anatomical Context for Ulcerative Colitis

MalaCards organs/tissues related to Ulcerative Colitis:

41
Colon, Testes, T Cells, Liver, Bone, Neutrophil, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Ulcerative Colitis:

19
Colon
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ulcerative Colitis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Ulcerative Colitis

Articles related to Ulcerative Colitis:

(show top 50) (show all 4012)
# Title Authors Year
1
Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes? ( 30199472 )
2019
2
Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice. ( 30205400 )
2019
3
Association of T Helper 1 Cytokine Gene Single Nucleotide Polymorphisms with Ulcerative Colitis and Crohn's Disease. ( 30134230 )
2019
4
Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center. ( 30134234 )
2019
5
A Case of Pulmonary Alveolar Proteinosis with Ulcerative Colitis. ( 29709938 )
2018
6
5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. ( 29951050 )
2018
7
Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. ( 29435325 )
2018
8
Long-Term Outcomes of Immunosuppression-NaA^ve Steroid Responders Following Hospitalization for Ulcerative Colitis. ( 29951797 )
2018
9
Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. ( 29450747 )
2018
10
The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. ( 29968483 )
2018
11
Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-I_B/MAPKs Pathway. ( 29959727 )
2018
12
The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis. ( 29941222 )
2018
13
Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis. ( 29928204 )
2018
14
Listeria Meningitis during Infliximab-based Treatment for Ulcerative Colitis. ( 29607962 )
2018
15
Fresh Fruit Juice of Opuntia dillenii Haw. Attenuates Acetic Acid-Induced Ulcerative Colitis in Rats. ( 29958056 )
2018
16
Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. ( 29424814 )
2018
17
Pyoderma Gangrenosum of the Preauricular Area with Ulcerative Colitis: A Case Report and Review. ( 29890815 )
2018
18
What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab? ( 29668955 )
2018
19
Pyoderma gangrenosum with its subtype affecting oral mucosa pyostomatitis vegetans following skin melanoma surgical excision in a patient with ulcerative colitis: a case report. ( 29760625 )
2018
20
An Overview of Molecular Profiles in Ulcerative Colitis-Related Cancer. ( 29945208 )
2018
21
Ileal pouch of ulcerative colitis and familial adenomatous polyposis patients exhibit modulation of autophagy markers. ( 29422639 )
2018
22
Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue. ( 29401083 )
2018
23
High Incidence of Recurrent Crohn's Disease Following Colectomy for Ulcerative Colitis Revealed with Long Follow-Up. ( 29282640 )
2018
24
Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis. ( 29541900 )
2018
25
A case of pemphigus vulgaris associated with ulcerative colitis. ( 29422810 )
2018
26
Case of pyoderma gangrenosum-like sporotrichosis caused by Sporothrix globosa in a patient with ulcerative colitis. ( 29488248 )
2018
27
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. ( 29850873 )
2018
28
Ulcerative colitis followed by the development of typical intestinal BehAset disease: A case report. ( 29443756 )
2018
29
Ulcerative colitis with Guillain-BarrAc syndrome: A case report. ( 29923987 )
2018
30
Ulcerative colitis: yet another paradoxical effect of tumour necrosis factor blockers? ( 29441549 )
2018
31
EBV colitis with ulcerative colitis: a double whammy. ( 29960963 )
2018
32
Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis. ( 29767352 )
2018
33
MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor I+-1. ( 29438285 )
2018
34
Management of iatrogenic perforation during colonoscopy in ulcerative colitis patients: a survey of gastroenterologists and colorectal surgeons. ( 29978362 )
2018
35
Altered Salivary Alpha-Amylase Secretion in Patients with Ulcerative Colitis. ( 29977288 )
2018
36
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. ( 29946178 )
2018
37
Duodenal amyloidosis secondary to ulcerative colitis. ( 29422811 )
2018
38
Introducing Traditional Herbal Medicine into Conventional Health Care in Treating Ulcerative Colitis: Primum Non Nocere. ( 29425926 )
2018
39
Partial to complete abrogation of the subepithelial macrophage barrier against the gut microbiota in patients with ulcerative colitis and Crohn's colitis. ( 29023984 )
2018
40
&amp;gt;0 g, a8o5 g A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. ( 29977035 )
2018
41
Gastrointestinal: Ulcerative colitis-associated duodenitis. ( 29659081 )
2018
42
Medical and Surgical Management of Pediatric Ulcerative Colitis. ( 29487489 )
2018
43
The Complexity of Renal Involvment in IBD-C3 Glomerulopathy in Ulcerative Colitis. ( 29522131 )
2018
44
Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis. ( 29361101 )
2018
45
Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature. ( 29546806 )
2018
46
Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threating Life Complication. ( 29931191 )
2018
47
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis. ( 29981298 )
2018
48
Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis. ( 29422812 )
2018
49
Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. ( 29427297 )
2018
50
Novel score predicts risk for cytomegalovirus infection in ulcerative colitis. ( 29940421 )
2018

Variations for Ulcerative Colitis

Expression for Ulcerative Colitis

LifeMap Discovery
Genes differentially expressed in tissues of Ulcerative Colitis patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CLDN8 claudin 8 Colon - 4.72 0.000
2 LCN2 lipocalin 2 Colon + 4.60 0.000
3 REG3A regenerating islet-derived 3 alpha Colon + 4.41 0.001
4 SLC26A2 solute carrier family 26 (anion exchanger), member 2 Colon - 4.19 0.000
5 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) Colon - 4.13 0.000
6 CXCL8 chemokine (C-X-C motif) ligand 8 Colon + 3.86 0.003
7 CXCL2 chemokine (C-X-C motif) ligand 2 Colon + 3.85 0.000
8 REG1A regenerating islet-derived 1 alpha Colon + 3.68 0.005
9 RGS3 regulator of G-protein signaling 3 Colon + 3.58 0.000
10 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Colon + 3.55 0.000
11 OLFM4 olfactomedin 4 Colon + 3.25 0.014
12 DEFA6 defensin, alpha 6, Paneth cell-specific Colon + 3.22 0.003
Search GEO for disease gene expression data for Ulcerative Colitis.

Pathways for Ulcerative Colitis

Pathways related to Ulcerative Colitis according to KEGG:

37
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630
3 Inflammatory bowel disease (IBD) hsa05321

Pathways related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CRP CXCL8 IL10 IL1B IL2 IL23R
2
Show member pathways
13.35 CXCL8 IL10 IL1B IL2 IL23R NOD2
3
Show member pathways
13.3 CXCL8 IL10 IL1B IL2 IL23R MYO9B
4
Show member pathways
12.95 ATG16L1 CXCL8 IL10 IL1B IL2 NOD2
5
Show member pathways
12.88 ABCB1 CXCL8 IL10 IL1B IL2 TNF
6 12.82 CXCL8 IL2 IL23R MLH1 MSH2
7
Show member pathways
12.78 CXCL8 IL1B IL2 TLR4 TNF
8 12.56 IL10 IL1B IL2 MPO TNF
9
Show member pathways
12.49 IL10 IL1B IL2 IL23R NOD2 TLR4
10
Show member pathways
12.45 IL10 IL1B IL2 IL23R MPO MSH2
11
Show member pathways
12.41 IL10 IL1B IL2 TNF
12
Show member pathways
12.34 CRP IL1B IL2 MPO TNF
13
Show member pathways
12.3 CXCL8 IL1B TLR4 TNF
14
Show member pathways
12.26 CXCL8 IL10 IL1B IL2 TNF
15
Show member pathways
12.26 IL10 IL1B IRGM TLR4 TNF
16
Show member pathways
12.23 CXCL8 IL1B MUC2 TNF
17
Show member pathways
12.22 IL10 IL1B IL2 TNF
18 12.21 IL10 IL1B NOD2 TLR4 TNF
19
Show member pathways
12.19 CXCL8 IL1B TLR4 TNF
20 12.19 MLH1 MSH2 TLR4 TNF
21 12.18 CXCL8 IL10 IL1B TNF
22 12 IL10 IL2 MPO TNF
23 11.99 CXCL8 IL1B IL2 TLR4 TNF
24 11.93 CXCL8 IL10 IL1B IL23R TNF
25 11.9 CXCL8 IL1B TLR4 TNF
26 11.87 CXCL8 IL1B TLR4 TNF
27 11.85 CXCL8 IL2 TLR4
28
Show member pathways
11.85 CXCL8 IL23R TLR4
29 11.81 CXCL8 IL1B TLR4
30 11.77 IL10 IL1B IL2 TNF
31
Show member pathways
11.75 CXCL8 IL2 TNF
32
Show member pathways
11.75 IL10 IL1B IL2 IL23R TLR4 TNF
33 11.72 IL10 IL1B IL2 TNF
34 11.66 CXCL8 IL1B TNF
35
Show member pathways
11.65 CXCL8 IL1B IL2 TNF
36